Tuesday, May 24, 2016

Rodman starts LabStyle Innovations at buy

Rodman starts LabStyle Innovations at buy

May 9, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw has initiated coverage of LabStyle Innovations (NASDAQ:DRIO) with a “buy” rating and $12 price target. The stock closed at $5.40 on Friday. LabStyle is an emerging digital health company focused on the monitoring and management of diabetes. Analyst Raghuram Selvaraju writes that the company has developed an integrated system to enable […]

HCW starts Strongbridge Biopharma at buy

HCW starts Strongbridge Biopharma at buy

April 27, 2016 by · Leave a Comment 

Tweet H.C. Wainwright has initiated coverage of Strongbridge Biopharma (NASDAQ:SBBP) with a “buy” rating and $15 price target. The stock closed at $5.23 on Tuesday. “Within the span of two years, Strongbridge has made material progress to strengthen its rare endocrine portfolio and had strategically planted its footing in a Cushing’s syndrome asset with comparatively […]

USPTO extends Oramed patent term

USPTO extends Oramed patent term

April 12, 2016 by · Leave a Comment 

Tweet The U.S. Patent and Trademark Office has issued a patent term adjustment (PTA) extending the patent term by 18 months for Oramed Pharmaceuticals’ (NASDAQ:ORMP) patent titled, “Methods and Compositions for Oral Administration of Proteins.” Oramed had previously received an allowance on the patent. The PTA increases the patent term from the standard 20 years […]

Oramed gets Indian patent for oral administration of proteins

Oramed gets Indian patent for oral administration of proteins

March 29, 2016 by · Leave a Comment 

Tweet Oramed Pharmaceuticals’ (NASDAQ:ORMP) patent for its invention, titled “Methods and Compositions for Oral Administrations of Proteins” has been granted by the Indian Patent Office. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule, ORMD-0801. Having completed multiple Phase 2a trials, a Phase 2b trial […]

Revive readies key clinical studies in gout and kidney stones

Revive readies key clinical studies in gout and kidney stones

March 1, 2016 by · Leave a Comment 

Tweet Revive Therapeutics (TSX-V:RVV; OTCQB:RVVTF) hopes to begin a pivotal Phase 2b clinical trial in mid-year with its Bucillamine drug candidate for the treatment of acute gout flares. “We believe that the Phase 2b data in gout will be a partner-enabling study with a large pharmaceutical company,” CEO, Fabio Chianelli, says in an interview with […]

Transition Therapeutics reports TT401 trial results

Transition Therapeutics reports TT401 trial results

February 1, 2016 by · Leave a Comment 

Tweet Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has reported results of a Phase 2 clinical study of drug candidate, TT401, for the treatment of Type 2 diabetes. TT401 is a once-weekly administered oxyntomodulin analog, with dual GLP-1 and glucagon agonist activity. TT401 development collaborator, Eli Lilly, performed the Phase 2 study, enrolling 420 Type 2 diabetes subjects […]

Can-Fite receives patent notice for sexual dysfunction drug

Can-Fite receives patent notice for sexual dysfunction drug

January 19, 2016 by · Leave a Comment 

Tweet Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent titled, “A3 Adenosine Receptor Allosteric Modulators”. The composition of matter patent protects the use of Can-Fite’s proprietary A3 Adenosine Receptor (A3AR) modulator, including the preparation of its pharmaceutical compositions and its use in […]

ReVENT Medical prepares for U.S. pivotal trial in sleep apnea

ReVENT Medical prepares for U.S. pivotal trial in sleep apnea

November 24, 2015 by · Leave a Comment 

Tweet Closely-held ReVENT Medical expects to begin a U.S. pivotal trial in the first half next year with its minimally invasive surgical solution to treat obstructive sleep apnea (OSA). “OSA is the most common type of sleep apnea and is caused by an obstruction of the upper airway, originating in the palate and/or the tongue,” […]

Can-Fite expands development of CF102 into NASH

Can-Fite expands development of CF102 into NASH

November 23, 2015 by · Leave a Comment 

Tweet Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) drug candidate, CF102, which is currently in Phase 2 trials for hepatocellular carcinoma (HCC), the most common form of liver cancer, will be expanded into the treatment for non-alcoholic steatohepatitis (NASH). NASH is characterized by excess fat in the liver along with inflammation and liver damage. While it resembles […]

Leerink starts Tobira Therapeutics at outperform

Leerink starts Tobira Therapeutics at outperform

October 23, 2015 by · Leave a Comment 

Tweet Leerink Partners has initiated coverage of Tobira Therapeutics (NASDAQ:TBRA) with an “outperform” rating and $24 price target in 12 months. The stock closed at $9.26 on Thursday. Tobira is aiming to capture the lion’s share of the currently untapped non-alcoholic steatohepatitis (NASH) market with Cenicriviroc (CVC), an oral, once-daily immunomodulator which directly targets inflammation […]

Next Page »

Email Newsletters with Constant Contact
Google+